Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD

Why It Matters

Demonstrating a clear reduction in limb‑loss outcomes positions sirolimus DCBs as a potential new standard of care for complex PAD, addressing a market segment with unmet therapeutic need.

Key Takeaways

• Sirolimus DCB reduced MALE to 8.8% vs 15%
• Unplanned amputation/revascularization fell to 23% vs 30.8%
• Trial enrolled 1,252 PAD patients, median age 75
• Sirolimus DCB matches paclitaxel efficacy, surpasses plain balloon
• US FDA IDE trials ongoing; European use imminent

Pulse Analysis

The SirPAD results arrive at a pivotal moment for peripheral artery disease (PAD) therapy, as clinicians grapple with the lingering safety controversy surrounding paclitaxel‑coated balloons. By delivering a 44% relative reduction in major adverse limb events, the sirolimus‑based MagicTouch device offers a compelling alternative that sidesteps the mortality concerns that have haunted paclitaxel products since the 2020 meta‑analysis. This hard‑outcome data, especially in a cohort where 40% presented with chronic limb‑threatening ischemia, underscores the clinical relevance of limus agents beyond surrogate patency metrics.

Beyond the headline numbers, the trial’s design—enrolling a broad, real‑world PAD population across femoropopliteal and below‑the‑knee (BTK) lesions—provides valuable insight into how sirolimus DCBs perform in heterogeneous disease states. The reduction in unplanned amputations and target‑lesion revascularizations suggests that sirolimus may promote more durable vessel healing, potentially translating into lower healthcare utilization and improved quality of life for older patients who often carry multiple comorbidities. While all‑cause mortality remained statistically unchanged, the safety profile aligns with existing evidence that limus drugs do not carry the same long‑term risk signals as paclitaxel.

Looking ahead, the ongoing LIMES trial in Europe will focus exclusively on BTK disease, a segment where therapeutic options are scarce and the need for limb‑saving interventions is acute. In the United States, the MagicTouch device is progressing through FDA Investigational Device Exemption studies, positioning it for regulatory clearance. If these follow‑up studies confirm the SirPAD findings, sirolimus DCBs could reshape reimbursement models and procedural algorithms, prompting vascular specialists to adopt a new paradigm that prioritizes both efficacy and safety in the management of complex PAD.